Egypt · Delayed Price · Currency is EGP GlaxoSmithKline S.A.E Statistics
Total Valuation
EGX:BIOC has a market cap or net worth of EGP 37.83 billion. The enterprise value is 39.42 billion.
| Market Cap | 37.83B |
| Enterprise Value | 39.42B |
Important Dates
The next estimated earnings date is Monday, November 16, 2026.
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | Jan 12, 2026 |
Share Statistics
EGX:BIOC has 83.51 million shares outstanding. The number of shares has decreased by -0.08% in one year.
| Current Share Class | 83.51M |
| Shares Outstanding | 83.51M |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 2.43M |
Valuation Ratios
The trailing PE ratio is 194.83.
| PE Ratio | 194.83 |
| Forward PE | n/a |
| PS Ratio | 10.46 |
| PB Ratio | 17.34 |
| P/TBV Ratio | 17.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 202.99 |
| EV / Sales | 10.89 |
| EV / EBITDA | 83.47 |
| EV / EBIT | 97.36 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.82.
| Current Ratio | 1.23 |
| Quick Ratio | 0.38 |
| Debt / Equity | 0.82 |
| Debt / EBITDA | 3.94 |
| Debt / FCF | -1.37 |
| Interest Coverage | 8.29 |
Financial Efficiency
Return on equity (ROE) is 9.15% and return on invested capital (ROIC) is 12.27%.
| Return on Equity (ROE) | 9.15% |
| Return on Assets (ROA) | 4.75% |
| Return on Invested Capital (ROIC) | 12.27% |
| Return on Capital Employed (ROCE) | 17.59% |
| Weighted Average Cost of Capital (WACC) | 5.52% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.71 |
| Inventory Turnover | 1.55 |
Taxes
In the past 12 months, EGX:BIOC has paid 24.56 million in taxes.
| Income Tax | 24.56M |
| Effective Tax Rate | 11.34% |
Stock Price Statistics
The stock price has increased by +771.70% in the last 52 weeks. The beta is 0.26, so EGX:BIOC's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | +771.70% |
| 50-Day Moving Average | 216.16 |
| 200-Day Moving Average | 102.97 |
| Relative Strength Index (RSI) | 61.60 |
| Average Volume (20 Days) | 761,896 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EGX:BIOC had revenue of EGP 3.62 billion and earned 194.18 million in profits. Earnings per share was 2.33.
| Revenue | 3.62B |
| Gross Profit | 724.08M |
| Operating Income | 386.44M |
| Pretax Income | 216.64M |
| Net Income | 194.18M |
| EBITDA | 440.83M |
| EBIT | 386.44M |
| Earnings Per Share (EPS) | 2.33 |
Balance Sheet
The company has 205.35 million in cash and 1.79 billion in debt, with a net cash position of -1.58 billion or -18.95 per share.
| Cash & Cash Equivalents | 205.35M |
| Total Debt | 1.79B |
| Net Cash | -1.58B |
| Net Cash Per Share | -18.95 |
| Equity (Book Value) | 2.18B |
| Book Value Per Share | 26.12 |
| Working Capital | 706.10M |
Cash Flow
In the last 12 months, operating cash flow was -1.03 billion and capital expenditures -267.64 million, giving a free cash flow of -1.30 billion.
| Operating Cash Flow | -1.03B |
| Capital Expenditures | -267.64M |
| Depreciation & Amortization | 54.38M |
| Net Borrowing | 1.44B |
| Free Cash Flow | -1.30B |
| FCF Per Share | -15.60 |
Margins
Gross margin is 20.01%, with operating and profit margins of 10.68% and 5.31%.
| Gross Margin | 20.01% |
| Operating Margin | 10.68% |
| Pretax Margin | 5.99% |
| Profit Margin | 5.31% |
| EBITDA Margin | 12.18% |
| EBIT Margin | 10.68% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.75, which amounts to a dividend yield of 0.18%.
| Dividend Per Share | 0.75 |
| Dividend Yield | 0.18% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 51.48% |
| Buyback Yield | 0.08% |
| Shareholder Yield | 0.26% |
| Earnings Yield | 0.51% |
| FCF Yield | -3.44% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
EGX:BIOC has an Altman Z-Score of 2.45 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.45 |
| Piotroski F-Score | 3 |